{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:49:59Z","timestamp":1761896999541},"reference-count":34,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,11,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Follicular lymphoma (FL) is an incurable but treatable disease with vast treatment options. Despite the abundance of efficacious treatment modalities, there is no universally agreed upon standard approach to treatment, particularly in the relapsed\/refractory setting. There is an increasing need for more robust and clinically available tools to risk-stratify patients and identify those likely to experience early relapse, which is currently recognized as the unmet need in FL. Additionally, the use of gene-expression profiling and next-generation sequencing techniques in recent years has led to a wealth of knowledge regarding the molecular drivers of lymphomagenesis. However, much of this knowledge is not currently available in the clinic to inform treatment decisions. Future studies are needed to generate clinically relevant predictive models adept at incorporating patient-specific and molecular features to inform management strategies along the entire disease continuum as treatment decisions should not be made in a vacuum with a one-size-fits-all approach. Sequencing of therapy in the management of relapsed FL should involve personalized decision-making for care plans that balance patient characteristics, preferences, and comorbidities with treatment-related factors such as efficacy, toxicity profile, and mechanisms of action to achieve a durable, quality remission.<\/jats:p>","DOI":"10.1182\/asheducation-2018.1.189","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T22:13:59Z","timestamp":1555452839000},"page":"189-193","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Sequencing of therapies in relapsed follicular lymphoma"],"prefix":"10.1182","volume":"2018","author":[{"given":"Loretta J.","family":"Nastoupil","sequence":"first","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"5","key":"2019111522591711300_B1","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular Lymphoma International Prognostic Index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"issue":"3","key":"2019111522591711300_B2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2141.2009.08065.x","article-title":"Validation of Follicular Lymphoma International Prognostic Index 2 (FLIPI2) score in an independent series of follicular lymphoma patients","volume":"149","author":"Arcaini","year":"2010","journal-title":"Br J Haematol"},{"issue":"23","key":"2019111522591711300_B3","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.1158\/1078-0432.CCR-13-1120","article-title":"A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine\u2013tositumomab","volume":"19","author":"Press","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2019111522591711300_B4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2019111522591711300_B5","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"32","key":"2019111522591711300_B6","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","article-title":"Population-based analysis of incidence and outcome of transformed non-Hodgkin\u2019s lymphoma","volume":"26","author":"Al-Tourah","year":"2008","journal-title":"J Clin Oncol"},{"issue":"26","key":"2019111522591711300_B7","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource","volume":"31","author":"Link","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111522591711300_B8","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/annonc\/mdl162","article-title":"The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma","volume":"17","author":"Gin\u00e9","year":"2006","journal-title":"Ann Oncol"},{"issue":"4","key":"2019111522591711300_B9","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nrc.2017.127","article-title":"From genetics to the clinic: a translational perspective on follicular lymphoma","volume":"18","author":"Huet","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2019111522591711300_B10","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/S2352-3026(14)70008-0","article-title":"Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies","volume":"1","author":"Trotman","year":"2014","journal-title":"Lancet Haematol"},{"issue":"9873","key":"2019111522591711300_B11","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"23","key":"2019111522591711300_B12","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.1158\/1078-0432.CCR-13-1120","volume":"19","author":"Press","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"9759","key":"2019111522591711300_B13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"issue":"23","key":"2019111522591711300_B14","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111522591711300_B15","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"issue":"21","key":"2019111522591711300_B16","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111522591711300_B17","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","article-title":"A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts","volume":"19","author":"Huet","year":"2018","journal-title":"Lancet Oncol"},{"issue":"12","key":"2019111522591711300_B18","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1023\/A:1008399623564","article-title":"High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol","volume":"11","author":"Brice","year":"2000","journal-title":"Ann Oncol"},{"issue":"18","key":"2019111522591711300_B19","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1200\/JCO.2006.09.8327","article-title":"Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up","volume":"25","author":"Rohatiner","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111522591711300_B20","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1200\/JCO.1997.15.2.445","article-title":"High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin\u2019s lymphoma","volume":"15","author":"Bierman","year":"1997","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111522591711300_B21","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/blood.V86.8.3257.3257","article-title":"Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma","volume":"86","author":"Bastion","year":"1995","journal-title":"Blood"},{"issue":"6","key":"2019111522591711300_B22","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1200\/JCO.1994.12.6.1177","article-title":"Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma","volume":"12","author":"Rohatiner","year":"1994","journal-title":"J Clin Oncol"},{"issue":"32","key":"2019111522591711300_B23","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111522591711300_B24","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1016\/S2352-3026(18)30001-2","article-title":"R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study","volume":"5","author":"Barr","year":"2018","journal-title":"Lancet Haematol"},{"issue":"9","key":"2019111522591711300_B25","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/cncr.22617","article-title":"Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan","volume":"109","author":"Witzig","year":"2007","journal-title":"Cancer"},{"issue":"22","key":"2019111522591711300_B26","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2017.76.3656","article-title":"Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study","volume":"36","author":"Cheson","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111522591711300_B27","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"issue":"35","key":"2019111522591711300_B28","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111522591711300_B29","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1182\/blood-2016-12-757740","article-title":"Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy","volume":"129","author":"Gopal","year":"2017","journal-title":"Blood"},{"issue":"suppl","key":"2019111522591711300_B30","volume":"35","author":"Andorsky","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111522591711300_B31","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10","key":"2019111522591711300_B32","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111522591711300_B33","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood-2017-09-804641","article-title":"Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial","volume":"131","author":"Bartlett","year":"2018","journal-title":"Blood"},{"issue":"26","key":"2019111522591711300_B34","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/189\/1251706\/hem01825.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/189\/1251706\/hem01825.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T05:18:16Z","timestamp":1573881496000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2018\/1\/189\/277563\/Sequencing-of-therapies-in-relapsed-follicular"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,11,30]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2018.1.189","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,30]]}}}